ChiCTR-INR-17012020 版本V1.0 版本创建时间2017/07/28 16:18:38 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-INR-17012020 

最近更新日期:

Date of Last Refreshed on:

2017-07-17 16:58:03 

注册时间:

Date of Registration:

2017-07-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

垂体腺瘤日间手术流程指定与安全性评价

Public title:

Protocol development and safety evaluation of pituitary adenomas in ambulatory surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

垂体腺瘤日间手术流程指定与安全性评价

Scientific title:

Protocol development and safety evaluation of pituitary adenomas in ambulatory surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王元 

研究负责人:

贺世明 

Applicant:

Wang Yuan 

Study leader:

He Shiming 

申请注册联系人电话:

Applicant telephone:

+86 18602910802

研究负责人电话:

Study leader's
telephone:

+86 15991387006

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

bladerunnerwang@gmail.com

研究负责人电子邮件:

Study leader's E-mail:

guodong.gao55@gmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

陕西省西安市灞桥区新寺路569号

研究负责人通讯地址:

陕西省西安市灞桥区新寺路569号

Applicant address:

569 Xinsi Road, Baqiao District, Xi'an, Shaanxi, China

Study leader's address:

569 Xinsi Road, Baqiao District, Xi'an, Shaanxi, China

申请注册联系人邮政编码:

Applicant postcode:

710038

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

第四军医大学唐都医院

Applicant's institution:

Tangdu Hospital, The Fourth Military Medical University

研究负责人所在单位:

第四军医大学唐都医院

Affiliation of the Leader:

Tangdu Hospital, The Fourth Military Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

201706

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

第四军医大学唐都医院伦理委员会

Name of the ethic committee:

Ethical Committee of Tangdu Hospital,Fourth Military Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2017-05-09 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

第四军医大学唐都医院神经外科

Primary sponsor:

Department of neurosurgery, Tangdu Hospital, Fourth Military Medical University

研究实施负责(组长)单位地址:

陕西省西安市灞桥区新寺路569号

Primary sponsor's address:

569 Xinsi Road, Baqiao District, Xi'an, Shaanxi, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

西安

Country:

China

Province:

Shaanxi

City:

Xi'an

单位(医院):

唐都医院

具体地址:

灞桥区新寺路569号

Institution
hospital:

Tangdu Hospital

Address:

569 Xinsi Road, Baqiao District, Xi'an, Shaanxi, China

经费或物资来源:

中国国家卫生和计划生育委员会

Source(s) of funding:

China National Health and Family Planning Commission

研究疾病:

垂体腺瘤  

Target disease:

Pituitary adenoma

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1. 完善并制定神经内镜下经鼻蝶垂体腺瘤切除术日间手术的规范标准。 2. 实施并评估神经内镜下经鼻蝶垂体腺瘤切除术日间手术的流程技术细节。 2. 探讨神经内镜下经鼻蝶垂体腺瘤切除术日间手术的安全性、有效性和可行性。  

Objectives of Study:

1. To improve and develop the standard treatment protocol of the day surgery for neuroendoscopic transsphenoidal pituitary adenoma; 2. To implement and evaluate the technical details of the treatment protocol of the day surgery for neuroendoscopic transsphenoidal pituitary adenoma; 3. To explore the safety, efficacy and feasibility of the treatment protocol of the day surgery for neuroendoscopic transsphenoidal pituitary adenoma.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

a. 肿瘤直径<3cm;
b. 肿瘤侵袭范围:Knosp分级 2级以下,Hardy Wilson分级 B级以下;
c. 无功能型腺瘤;
d. 年龄介于18-65周岁;
e. 美国麻醉协会(ASA)分级Ⅰ-Ⅱ级;
f. KPS评分≥90分;
g. 了解、同意并配合日间手术。

Inclusion criteria

1. Tumor diameter <3cm;
2. Tumor invasion range: Knosp grading level 2 or less, Hardy Wilson grade B below;
3. Nonfunctional adenoma;
4. Aged between 18-65 years old;
5. American Association of Anesthesia (ASA) grades I - II;
6. KPS score ≥90 points;
7. Patients who understand, agree and cooperate with daytime surgery.

排除标准:

a. 手术区域存在感染或炎症者;
b. 严重并发症疾病(心脏疾病、血液系统、呼吸系统、消化系统等)患者;
c. 精神病或严重心理疾病患者;
d. 女性6个月内有育儿计划、处于妊娠期或哺乳期的患者;
e. 研究者认为其他不适合入组的患者。

Exclusion criteria:

1. Infection or inflammation in the surgical area;
2. Serious complications of disease (heart disease, blood system, respiratory system, digestive system, etc.) patients;
3. Patients with mental illness or serious mental illness;
4. Female within 6 months of child care program, in pregnancy or lactation patients;
5. Other patients who were considered unsuitable for inclusion in the study.

研究实施时间:

Study execute time:

From 2017-07-20 00:00:00 To 2017-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-07-20 00:00:00 To 2017-11-30 00:00:00

干预措施:

Interventions:

组别:

日间手术组

样本量:

50

Group:

Day surgery group

Sample size:

干预措施:

神经内镜经鼻蝶垂体腺瘤日间手术治疗方案

干预措施代码:

Intervention:

Day surgery protocol

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

常规内镜下经鼻蝶手术治疗方案

干预措施代码:

Intervention:

Neuroendoscopic transsphenoidal pituitary adenoma

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China

Province:

Shaanxi

City:

Xi'an

单位(医院):

唐都医院 

单位级别:

三甲 

Institution
hospital:

Tangdu Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

住院时间

指标类型:

主要指标

Outcome:

Length of hospital stay

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

非手术相关并发症

指标类型:

次要指标

Outcome:

Non-surgical related complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术相关并发症

指标类型:

次要指标

Outcome:

Surgical related complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日间手术脱落率

指标类型:

主要指标

Outcome:

Drop rate of the day surgery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后住院时间

指标类型:

次要指标

Outcome:

Length of stay after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉后出院评分

指标类型:

次要指标

Outcome:

Post-Anesthesia Score,PAS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

KPS评分

指标类型:

次要指标

Outcome:

KPS score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肿瘤组织

组织:

鞍区垂体

Sample Name:

使用后保存

Tissue:

Pituitary Sellae

人体标本去向

使用后保存  

说明

保存于病理组织标本库20年

Fate of sample:

Preservation after use  

Note:

Preserved in the histopathological tissue specimen library for 20 years

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由统计软件R产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Random sequence generated by R.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

在中国临床试验注册中心共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Sharing in Chinese clinical trial registry

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用excel表进行数据保存和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The original data was saved by excel spreadsheet.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2017-07-17 16:58:03